S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial

S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial

Summary: Background: There are currently limited systemic treatment options for patients with advanced neuroendocrine tumours (NETS) and the efficacy of existing treatments is sub-optimal. We evaluated the efficacy and safety of Tegafur/gimeracil/oteracil/potassium capsules (S-1)/Temozolomide with...

Full description

Bibliographic Details
Main Authors: Yihebali Chi, Lijie Song, Weili Liu, Yuhong Zhou, Yadong Miao, Weijia Fang, Huangying Tan, Susheng Shi, Hai Jiang, Jianming Xu, Ru Jia, Bo Zheng, Liming Jiang, Jiuda Zhao, Rui Zhang, Huijing Tan, Yuehua Wang, Qichen Chen, Minjie Yang, Xi Guo, Zhou Tong, Zhirong Qi, Fuxing Zhao, Xiaofei Yan, Hong Zhao
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:EClinicalMedicine
Subjects:
S-1
Temozolomide
Thalidomide
Neuroendocrine tumours
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022003972

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022003972

Similar Items